经导管肝动脉化疗栓塞术联合索拉非尼治疗晚期肝细胞癌的效果

摘要

目的 评估经导管肝动脉化疗栓塞术(TACE)与TACE联合索拉非尼治疗晚期肝细胞癌的效果.方法 回顾性分析2012年1月～2016年1月在川北医学院附属医院住院的晚期肝细胞癌患者88例的临床资料,将患者分为TACE组和TACE+索拉非尼组(联合组),每组44例.比较两组疾病控制率、不良反应发生率、半年生存率、1年生存率.结果 联合组疾病控制率为54.5％,高于TACE组(29.5％),差异有统计学意义(P＜0.05);联合组不良反应发生率为81.8％,TACE组不良反应发生率为84.1％,差异无统计学意义(P＞0.05);联合组半年生存率、1年生存率分别为59.1％、47.7％,均明显高于TACE组(36.4％、25.0％),差异均有统计学意义(P＜0.05).结论 TACE联合索拉非尼治疗晚期肝细胞癌是一种可行的治疗方式,疗效较好,患者远期生存期得到延长,且耐受良好,值得临床推广.%Objective To assess the therapeutic effect of transcatheter arterial chemoembolization (TACE) combined with Sorafenib in the treatment of advanced hepatocellular carcinoma.Methods The clinical data of 88 patients with advanced hepatocellular carcinoma hospitalized in the Affiliated Hospital of North Sichuan Medical College from January 2012 to January 2016 was analyzed retrospectively.The patients were divided into TACE group and TACE + Sorafenib group (combined group),with 44 cases in each group.The disease control rate,incidence of adverse reactions,halfyear survival rate,one-year survival rate of the two groups were analyzed.Results The disease control rate of combined group was 54.5％,which was higher than that of TACE group (29.5％),the difference was statistically significant (P ＜ 0.05);the incidence of adverse reactions in combined group was 81.8％,which of TACE group was 84.1％,there was no significant difference between the two groups (P ＞ 0.05).The half-year survival rate and one-year survival rate in combined group was 59.1％,47.7％ respectively,which was significantly higher than those of TACE group (36.4％,25.0％),the differences were all statistically significant (all P ＜ 0.05).Conclusion TACE combined with Sofafenib in the treatment of advanced hepatocellular carcinoma is feasible,the therapeutic effect is good,the long-term lifetime is prolonged,the tolerance is well,which is worthy of clinical promotion.